Cite
HARVARD Citation
Visentin, A. et al. (2019). BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. British journal of haematology. pp. 193-197. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Visentin, A. et al. (2019). BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. British journal of haematology. pp. 193-197. [Online].